Skip to main content Accessibility help
×
Home
  • Print publication year: 2015
  • Online publication date: November 2015

20 - Management of cancer of the kidney

Summary

Introduction

Cancer of the kidney represents 4% of adult malignancies. Men are more frequently affected than women, and it commonly occurs between the ages of 50 and 70 years. More than 30% of patients present with metastatic disease. The majority of malignant tumours are adenocarcinomas, arising from the proximal renal tubular epithelium. These tumours were previously called hypernephroma because it was believed that they originated from adrenal rests, but they are correctly termed renal cell carcinoma (RCC). The main focus of this chapter is the management of RCC. Transitional cell carcinoma of the renal pelvis accounts for 5% of all renal malignancies, and is covered separately at the end of the chapter.

Types of kidney tumour

Kidney tumours can be benign, malignant primary or metastatic. Benign tumours include cysts (simple, complex, multiple), inflammatory (infection, infarction), adenoma and oncocytoma. Malignant primary tumours include RCC, lymphoma, sarcoma and renal pelvis tumours (5% of malignant renal cancers arise from the renal pelvis, and more than 90% of these are transitional cell carcinoma).

Anatomy

The kidneys are retroperitoneal structures that lie between the eleventh rib and the transverse process of the third lumbar vertebral body, each approximately 11 cm in length, the right lying slightly lower than the left. Each kidney is surrounded by perinephric fat which in turn is covered by Gerota's fascia. The right kidney abuts the liver and stomach and the left, the spleen, stomach and pancreas. The lymphatics drain along the renal vessels, on the right draining to paracaval and aortocaval nodes, and on the left to the para-aortic region.

Incidence and epidemiology

Over 10,000 new cases of kidney cancer were diagnosed in the UK in 2011 resulting in approximately 4200 deaths (Cancer Research UK website accessed July 2014). In the last 10 years kidney cancer incidence rates in the UK have increased by almost a third, and unlike in some other cancers, the death rate is still rising. Kidney cancer occurs most commonly in people 50–80 years of age. Men are more frequently affected than women; the male-to-female ratio is 5:3. It is the seventh most common cancer in men and tenth most common cancer in women in the UK.

Aso, Y. and Homma, Y. (1992). A survey of incidental renal cell carcinoma in Japan. J. Urol., 147, 340–343.
Atkins, M., Regan, M., McDermott, D., et al. (2005). Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin. Cancer Res., 11, 3714–3721.
Atzpodien, J., Kirchner, H., Illiger, H. J., et al. (2001). IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br. J. Cancer, 85, 1130–1136.
Bell, E. T. (1950). Renal Diseases, 2nd edn. Philadelphia, PA: Lea and Febiger.
Bosniak, M. A. (1986). The current radiological approach to renal cysts. Radiology, 158, 1–10.
Clark, J., Atkins, M., Urba, W., et al. (2003). Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J. Clin. Oncol., 21, 3133–3140.
Coppin, C., Porzsolt, F., Awa, A., et al. (2005). Immunotherapy for advanced renal cell cancer. Cochrane Database Syst. Rev., 1, CD001425.
Eble, J. N., Sauter, G., Epstein, J.I., et al. (2004). Pathology and Genetics. Tumors of the Urinary System and Male Genital Organs.Lyon: IARC Press.
Escudier, B., Pluzanska, A., Koralewski, P., et al. (2007). Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet, 370, 2103–2111.
Escudier, B., Porta, C., Bono, P., et al. (2014). Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study. J. Clin. Oncol., 32, 1412–1418.
Finney, R. (1973). Radiotherapy in the treatment of hypernephroma: a clinical trial. Br. J. Urol., 45, 26–40.
Flanigan, R. C., Salmon, S. E., Blumenstein, B. A., et al. (2001). Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N. Engl. J. Med., 345, 1655–1659.
Fuhrman, S. A., Lasky, L. C., Limas, C., et al. (1982). Prognostic significance of morphological parameters in renal cell carcinoma. Am. J. Surg. Pathol., 6, 655–663.
Gore, M. E., Griffin, C. L., Hancock, B., et al. (2010). Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Lancet, 375, 641–648.
Heng, D. Y., Xie, W., Regan, M. M., et al. (2009). Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J. Clin. Oncol., 27, 5794–5799.
Heng, D. Y., Xie, W., Regan, M. M., et al. (2013). External validation and comparison with other models of the International Metastatic Renal Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol., 14, 141–148.
Hudes, G., Carducci, M., Tomczak, P., et al. (2007). Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med., 356, 2271–2281.
Janowitz, T., Welsh, S. J., Zaki, K., et al. (2013). Adjuvant therapy in renal cell carcinoma – past, present, and Future. Semin. Oncol., 40, 482–491.
Jocham, D., Richter, A., Hoffmann, L., et al. (2004). Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet, 363, 594–599.
Kjaer, M. (1988). The role of medroxyprogesterone acetate (MPA) in the treatment of renal adenocarcinoma. Cancer Treat. Rev., 15, 195–209.
Kjaer, M., Frederiksen, P. L. and Engelholm, S. A. (1987). Postoperative radiotherapy in stage II and III renal adenocarcinoma: a randomised trial by the Copenhagen Renal Cancer Study Group. Int. J. Radiat. Oncol. Biol. Phys., 13, 665–672.
Leibovich, B. C., Blute, M. L., Cheville, J. C., et al. (2003). Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.Cancer, 97, 1663.
Messing, E., Manola, J., Wilding, G., et al. (2003). Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J. Clin. Oncol., 21, 1214–1222.
Mickisch, G. H., Garin, A., van Poppel, H., et al. (2001). Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon-alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet, 358, 966–970.
Montie, J. E., Stewart, B. H., Straffon, R. A., et al. (1977). The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J. Urol., 117, 272–275.
Motzer, R. J., Escudier, B., Oudard, S., et al. (2008). Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet, 372, 449–456.
Motzer, R. J., Hutson, T.E., Tomczak, P., et al. (2009). Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol., 27, 3584–3590.
Motzer, R. J., Escudier, B., Tomczak, P., et al. (2013a). Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol., 14, 552–562.
Motzer, R. J., Hutson, T. E., Cella, D., et al. (2013b). Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N. Engl. J. Med., 36, 722–731.
Motzer, R. J., Hutson, T. E., McCann, L., et al. (2014). Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N. Engl. J. Med., 370, 1769–1770.
Murphy, W. M., Beckwith, J. B. and Farrow, G. M. (1994). Tumors of the kidney, bladder, and related urinary structures. In: Atlas of Tumor Pathology, 3rd edn. Bethesda, MD: Armed Force Institute of Pathology.
Negrier, S., Gomez, F., Douillard, J. Y., et al. (2005). Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français D'Immunothérapie. World J. Urol., 23, 161–165.
Negrier, S., Perol, D., Ravaud, A., et al. (2007). Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis. Cancer, 110, 2468–2477.
O'Dea, M. J., Zincke, H., Utz, D. C., et al. (1978). The treatment of renal cell carcinoma with solitary metastasis. J. Urol., 120, 540–542.
Rini, B.I., Halabi, S., Rosenberg, J. E., et al. (2008). Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol., 26, 5422–5428.
Sternberg, C. N., Davis, I. D., Mardiak, J., et al. (2010). Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J. Clin. Oncol., 28, 1061–1068.
Tada, S., Yamagishi, J., Kobayashi, H., et al. (1983). The incidence of simple renal cyst by computed tomography. Clin. Radiol., 34, 437–439.
UICC. (2009). TNM Classification of Malignant Tumours, 7th edn, ed. Sobin, L. H., Gospodarowicz, M. and Wittekind, Ch.. New York: Wiley-Liss, pp. 255–257.
Yagoda, A., Abi-Rached, B., Petrylak, D., et al. (1995). Chemotherapy for advanced renal-cell carcinoma: 1983–1993. Semin. Oncol., 22, 42–60.